Table of Contents
Executive Summary
- Overview on drug delivery industry
- Oral drug delivery system
- Injectable drug delivery system
- Pulmonary drug delivery system
- Transdermal drug delivery system
Chapter 1 Overview of drug delivery
- industry
- Summary
- What is this report about?
- Methodology
- Drug delivery overview
- Role of drug delivery in the pharma landscape
- Revenue boosters for pharma companies
- Patent extension and protection from generic competition
- Reformulation of existing products
- Optimizing returns on R&D investment
- Compliance, bioavailability and safety benefits
- From drug delivery to specialty pharma
- Markets for drug delivery systems
- Oral drug delivery system
- Pulmonary
- Injectable
- Transdermal
- Market dynamics
Chapter 2 Oral drug delivery system
- Summary
- Synopsis
- Oral drug delivery technologies
- Technologies for fast-dissolving and taste-masking pills
- Controlled oral drug delivery
- Types of controlled release
- Dynamics of oral drug delivery market
- Biovail
- Key technologies
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Expanding its presence in diverse geographical areas
- Deriving growth from strategic alliances
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Elan
- Key technologies
- NanoCrystal technology
- OCR technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Alzheimer' s disease
- Pipeline products
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- SkyePharma
- Key technologies
- Oral drug delivery technologies
- Inhalation technologies
- Insoluble drug delivery (IDD) technology
- Therapeutic focus
- Products portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Focus on building pipeline of products
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 3 Injectable drug delivery system
- Summary
- Synopsis
- Injectable drug delivery technologies
- Needleless injection device technology
- Sustained/controlled release technology
- PEGylation
- Therapeutic focus
- Dynamics of the injectable drug delivery market
- Alkermes
- Introduction
- Key technologies
- Medisorb injectable technology
- AIR pulmonary drug delivery technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Bioject
- Introduction
- Key technologies
- Needle-free injection technology
- Therapeutic Focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Developing clinical research collaborations
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- QLT
- Key technologies
- Atrigel drug delivery system
- PDT
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent company financials
- Growth strategies
- Focus on key therapeutic areas
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 4 Pulmonary drug delivery system
- Summary
- Synopsis
- Inhaled formulations
- Therapeutic focus
- Dynamics of the pulmonary drug delivery market
- Nektar Therapeutics
- Key technologies
- Dry powder pulmonary technology
- Liquid pulmonary technology
- PEGylation technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Shifting focus from drug delivery to become a specialty pharma
- company
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Aradigm
- Key technologies
- AERx pulmonary drug delivery system
- Liposomal Formulations
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- 3M
- Key technologies
- Pulmonary drug delivery technology
- Transdermal drug delivery technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Growth strategies
Chapter 5 Transdermal drug delivery system
- Summary
- Synopsis
- Transdermal drug delivery technologies
- Passive formulations
- Active formulations
- Therapeutic focus
- Dynamics of the transdermal drug delivery market
- Antares
- Key technologies
- Advanced transdermal delivery
- Injection devices
- Easy Tec fast melt oral disintegrating tablets
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Noven
- Key technologies
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Alza
- Key technologies
- D-Trans
- E-Trans
- Macroflux
- Stealth
- Alzamer
- Oros
- Therapeutic focus
- Product portfolio and pipeline candidate
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 6 Conclusion
- Financials
- Growth strategies
- Outlook
- Glossary
- Index
List of Figures
- Figure 1.1: Drug delivery technologies are revenue boosters for pharma
companies
- Figure 1.2: Procardia XL patent expiry
- Figure 1.3: Cardizem' s reformulation strategy
- Figure 1.4: Compliance, bioavailability and safety benefits via effectice
drug delivery
- Figure 1.5: Positioning of key drug delivery companies
- Figure 1.6: Key drug delivery systems market share, 2006
- Figure 2.7: Biovail financial performance, $m, 2003-2007
- Figure 2.8: Biovail SWOT analysis
- Figure 2.9: Elan financial performance, 2003-2007 ($m)
- Figure 2.10: Elan SWOT analysis
- Figure 2.11: SkyePharma financial performance, $m, 2003-2007
- Figure 2.12: SkyePharma SWOT analysis
- Figure 3.13: Alkermes financial performance, 2003-2007
- Figure 3.14: Alkermes SWOT analysis
- Figure 3.15: Bioject financial performance, 2003-2007 ($m)
- Figure 3.16: Bioject SWOT analysis
- Figure 3.17: QLT financial performance, 2003-2007 ($m)
- Figure 3.18: QLT SWOT analysis
- Figure 4.19: Nektar financial performance, 2003-2007 ($m)
- Figure 4.20: Nektar SWOT analysis
- Figure 4.21: Aradigm financial performance, 2003-2007 ($m)
- Figure 4.22: Aradigm SWOT analysis
- Figure 5.23: Antares financial performance, 2003-2007 ($m)
- Figure 5.24: Antares SWOT analysis
- Figure 5.25: Noven financial performance, 2003-2007 ($m)
- Figure 5.26: Noven SWOT analysis
- Figure 5.27: Alza SWOT analysis
- Figure 6.28: Comparative analysis of key drug delivery companies (I)
- Figure 6.29: Comparative analysis of key drug delivery companies (II)
List of Tables
- Table 2.1: Biovail snapshot
- Table 2.2: Biovail oral marketed products
- Table 2.3: Biovail oral product sales, 2006-2007 ($m)
- Table 2.4: Biovail oral product pipeline
- Table 2.5: Biovail financial performance, 2003-2007 ($m)
- Table 2.6: Elan snapshot
- Table 2.7: Elan oral marketed products
- Table 2.8: Elan NanoCrystal product pipeline
- Table 2.9: Elan financial performance, 2003-2007 ($m)
- Table 2.10: SkyePharma snapshot
- Table 2.11: SkyePharma oral marketed products
- Table 2.12: Skye Pharma oral product pipeline
- Table 2.13: SkyePharma financial performance, 2003-2007
- Table 3.14: Alkermes snapshot
- Table 3.15: Alkermes injectable marketed products
- Table 3.16: Alkermes injectable product sales, 2006-2007 ($m)
- Table 3.17: Alkermes injectable product pipeline
- Table 3.18: Alkermes financial performance, 2003-2007 ($m)
- Table 3.19: Bioject snapshot
- Table 3.20: Bioject injectable marketed products
- Table 3.21: Bioject injectable product sales, 2006-2007 ($m)
- Table 3.22: Bioject financial performance, 2003-2007 ($m)
- Table 3.23: QLT snapshot
- Table 3.24: QLT injectable marketed products
- Table 3.25: QLT injectable product sales, 2006-2007 ($m)
- Table 3.26: QLT injectable product pipeline
- Table 3.27: QLT financial performance, 2003-2007 ($m)
- Table 4.28: Nektar snapshot
- Table 4.29: Nektar pulmonary marketed products
- Table 4.30: Nektar pulmonary product sales, 2006-2007 ($m)
- Table 4.31: Nektar pulmonary product pipeline
- Table 4.32: Nektar financial performance, 2003-2007 ($m)
- Table 4.33: Aradigm snapshot
- Table 4.34: Aradigm pulmonary product pipeline
- Table 4.35: Aradigm financial performance, 2003-2007 ($m)
- Table 4.36: 3M snapshot
- Table 4.37: 3M pulmonary marketed products
- Table 5.38: Antares snapshot
- Table 5.39: Antares transdermal marketed products
- Table 5.40: Antares transdermal product pipleine
- Table 5.41: Antares financial performance, 2003-2007 ($m)
- Table 5.42: Noven snapshot
- Table 5.43: Noven transdermal marketed products
- Table 5.44: Noven transdermal product pipeline
- Table 5.45: Noven financial performance, 2003-2007 ($m)
- Table 5.46: Alza snapshot
- Table 5.47: Alza transdermal marketed products
|
Related Report
|
View Cart
